{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:01:58Z","timestamp":1790820118613,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100021852","name":"Centre Hospitalier Universitaire de Poitiers","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021852","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jtha.2025.06.012","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T10:57:17Z","timestamp":1749898637000},"page":"3220-3230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Thromboembolism in transplant-ineligible multiple myeloma patients on triplet\/quadruplet therapy: a post hoc analysis of BENEFIT trial"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0879-6261","authenticated-orcid":false,"given":"Emilie","family":"Chalayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Frere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Daguenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lecompte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Tardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilhame","family":"Bounouara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Sapet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Bobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Harel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Decaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Belhadj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Macro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Corre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Avet\u2013Loiseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Karlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Facon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Perrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Hulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salomon","family":"Manier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Frenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.06.012_bib1","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1538-7836.2011.04215.x","article-title":"Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis","volume":"9","author":"Carrier","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.012_bib2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1182\/asheducation-2010.1.437","article-title":"Thrombosis in multiple myeloma","volume":"2010","author":"Kristinsson","year":"2010","journal-title":"Hematology"},{"key":"10.1016\/j.jtha.2025.06.012_bib3","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol 2022"},{"key":"10.1016\/j.jtha.2025.06.012_bib4","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.06.012_bib5","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtha.2025.06.012_bib6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","article-title":"NCCN Guidelines insights: multiple myeloma, version 3.2022: featured updates to the NCCN guidelines","volume":"20","author":"Callander","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jtha.2025.06.012_bib7","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.3324\/haematol.2022.280893","article-title":"Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel","volume":"107","author":"De Stefano","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2025.06.012_bib8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.thromres.2023.11.021","article-title":"Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: results of a large survey and clinical guidance recommendations from the IFM group","volume":"233","author":"Frenzel","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.06.012_bib9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.critrevonc.2018.02.003","article-title":"Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: critical review of the literature","volume":"124","author":"Annibali","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jtha.2025.06.012_bib10","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2025.06.012_bib11","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","article-title":"Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide","volume":"119","author":"Larocca","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.012_bib12","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.1038\/s41467-021-25634-z","article-title":"The E3 ubiquitin ligase component, Cereblon, is an evolutionarily conserved regulator of Wnt signaling","volume":"12","author":"Shen","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtha.2025.06.012_bib13","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/bloodadvances.2023010080","article-title":"Thrombospondin-1 is an endogenous substrate of cereblon responsible for immunomodulatory drug\u2013induced thromboembolism","volume":"8","author":"Hatakeyama","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2025.06.012_bib14","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.06.012_bib15","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","article-title":"Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial","volume":"30","author":"Leleu","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jtha.2025.06.012_bib16","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jtha.2025.06.012_bib17","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/jth.15758","article-title":"Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: lessons from the substudy of IFM\/DFCI 2009 cohort","volume":"20","author":"Chalayer","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.06.012_bib18","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jtha.2025.06.012_bib19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/0272989X0102100106","article-title":"Prognostic modeling with logistic regression analysis: in search of a sensible strategy in small data sets","volume":"21","author":"Steyerberg","year":"2001","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jtha.2025.06.012_bib20","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1080\/10428194.2021.1910687","article-title":"Venous thromboembolism in patients with multiple myeloma receiving daratumumab-based regimens: a post hoc analysis of phase 3 clinical trials","volume":"62","author":"Wang","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtha.2025.06.012_bib21","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/bjh.18432","article-title":"Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: analysis of vascular thrombotic events in the GRIFFIN study","volume":"199","author":"Sborov","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.06.012_bib22","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood.2020005125","article-title":"Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials","volume":"136","author":"Bradbury","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.06.012_bib23","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/S0049-3848(21)00255-3","article-title":"IMPEDE VTE vs SAVED scores to predict the risk of venous thromboembolism in newly diagnosed multiple myeloma with immunomodulatory drugs: how to choose?","volume":"200","author":"Teste","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.06.012_bib24","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/cncr.32682","article-title":"Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: a systematic review and meta-analysis","volume":"126","author":"Chakraborty","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.jtha.2025.06.012_bib25","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/bjh.15392","article-title":"Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens","volume":"185","author":"Storrar","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.06.012_bib26","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/ajh.25459","article-title":"Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study","volume":"94","author":"Pegourie","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2025.06.012_bib27","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjh.16653","article-title":"Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents","volume":"190","author":"Cornell","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.06.012_bib28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.thromres.2022.03.001","article-title":"Safety and efficacy of apixaban as thromboprophylaxis in myeloma patients receiving chemotherapy: a prospective cohort study","volume":"213","author":"Sayar","year":"2022","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.06.012_bib29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/bjh.17772","article-title":"Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis","volume":"196","author":"Piedra","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.06.012_bib30","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1080\/10428194.2020.1713321","article-title":"Recent developments and persisting challenges in the prevention and treatment of venous thromboembolism in patients with hematological malignancies","volume":"61","author":"Sorigue","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtha.2025.06.012_bib31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-2143(96)90116-X","article-title":"Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma","volume":"128","author":"Carr","year":"1996","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.jtha.2025.06.012_bib32","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3390\/molecules30030668","article-title":"The proteome content of blood clots observed under different conditions: successful role in predicting clot amyloid(ogenicity)","volume":"30","author":"Kell","year":"2025","journal-title":"Molecules"},{"key":"10.1016\/j.jtha.2025.06.012_bib33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/1471-2369-13-107","article-title":"Proteinuria and hypoalbuminemia are risk factors for thromboembolic events in patients with idiopathic membranous nephropathy: an observational study","volume":"13","author":"Kumar","year":"2012","journal-title":"BMC Nephrol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625003988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625003988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:23:58Z","timestamp":1790817838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625003988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1538783625003988"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.06.012","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thromboembolism in transplant-ineligible multiple myeloma patients on triplet\/quadruplet therapy: a post hoc analysis of BENEFIT trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}